Ocrevus Zunovo Drug Interactions: 250 Major, 34 Moderate
Ocrevus Zunovo (Ocrelizumab And Hyaluronidase) Drug Interactions
Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Ocrevus Zunovo. Always confirm against the full prescribing information.
100 interactions
Anthrax immune globulin human
The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Ocrelizumab.
Level 2 evidence
AstraZeneca COVID-19 Vaccine
The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Ocrelizumab.
The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Ocrelizumab.
Level 2 evidence
Acetylsalicylic acid
The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Acetylsalicylic acid.
Level 1 evidence
Aducanumab
The risk or severity of adverse effects can be increased when Ocrelizumab is combined with Aducanumab.
Level 2 evidence
Alirocumab
The risk or severity of adverse effects can be increased when Alirocumab is combined with Ocrelizumab.
Level 2 evidence
Allogeneic processed thymus tissue
The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Ocrelizumab.
Level 2 evidence
Amitriptyline
The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Amitriptyline.
Level 1 evidence
Amivantamab
The risk or severity of adverse effects can be increased when Ocrelizumab is combined with Amivantamab.
Level 2 evidence
Ansuvimab
The risk or severity of adverse effects can be increased when Ocrelizumab is combined with Ansuvimab.
Level 2 evidence
Anthrax vaccine
The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Ocrelizumab.
Level 1 evidence
Aripiprazole
The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Aripiprazole.
Level 1 evidence
Enter your NPI to unlock 54 major interactions for Ocrevus Zunovo
Ocrevus Zunovo (Ocrelizumab And Hyaluronidase) has 479 documented drug interactions. Always review the full list with a pharmacist before co-prescribing.
Ocrevus Zunovo (Ocrelizumab And Hyaluronidase) has 250 major, 34 moderate, and 195 minor documented interactions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Ocrevus Zunovo. Always confirm against the full prescribing information.